

# Clinical trials of lispro + NPH

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 diabetes type 2

| Trial   | Treatments  | Patients  | Trials design and methods |
|---|---|---|---------------------------|
| <b>lispro + NPH vs NPH + SU</b>                       |   |   |                           |
| <b>Bastyr , 1999</b><br>n=NA<br>follow-up:            | preprandial insulin lispro plus bedtime<br>NPH insulin<br>versus<br>bedtime neutral protamine Hagedorn<br>(NPH) insulin plus sulfonylurea | -   |                           |
| <b>lispro + NPH vs NPH twice daily</b>                |   |   |                           |
| <b>Ceriello , 2007</b><br>n=NA<br>follow-up: 12 weeks | premeal insulin lispro+bedtime neutral<br>protamine Hagedorn (NPH)<br>versus<br>twice-daily NPH   | patients with type 2 diabetes treated by a<br>2-month lead-in with twice-daily NPH<br>treatment | Cross over<br>open-label  |

More details and results :

- insulin therapy for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q548>

## References

### **Bastyr, 1999:**

Bastyr EJ, Johnson ME, Trautmann ME, Anderson JH, Vignati L, Insulin lispro in the treatment of patients with type 2 diabetes mellitus after oral agent failure. Clin Ther 1999;21:1703-14. [[10566566](#)]

### **Ceriello, 2007:**

Ceriello A, Del Prato S, Bue-Valleskey J, Beattie S, Gates J, de la Pea A, Malone J, Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors. J Diabetes Complications ;21:20-7. [[17189870](#)]  
[10.1016/j.jdiacomp.2005.11.005](#)